MET and lung adenocarcinoma: It is previously reported that patients with lung adenocarcinoma with carcinogenic mutations at MET exon 14 RNA splice acceptor and donor sites could benefit from treatment with MET inhibitors crizotinib and cabozantinib, identifying a novel therapeutic target for lung adenocarcinoma [9].